Researcher
Pieter Van Der Veken
- Research Expertise:Medicinal chemistry & drug discovery, pharmaceutical chemistry, organic chemistry & organic synthesis
- Keywords:ORGANIC CHEMISTRY, MEDICINAL CHEMISTRY, DRUG DISCOVERY, Pharmacy and pharmacology
- Disciplines:(Bio)molecular modelling and design, Characterisation of biologically active (macro)molecules, Medicinal and biomolecular chemistry not elsewhere classified, Bio-organic chemistry, Organic chemical synthesis, Medicinal chemistry
- Research techniques:Drug design, organic synthesis, characterization of molecules via NMR spectroscopy, mass spectrometry and other analytical techniques
- Users of research expertise:Pharmaceutical and biotech-industry
Affiliations
- Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2003 → Today
Projects
1 - 10 of 74
- Druglike FAPIs with maximal target residence time: chemical discovery and biological characterization.From1 Jan 2024 → TodayFunding: IOF - technology concept exploration
- Potent intra-tumoral autophagy blocking with kinase PROTACs and inhibitors.From1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Cell-type specific delivery of autophagy inducers as a strategy to address localized autophagy impairment in diseaseFrom1 Nov 2023 → TodayFunding: FWO fellowships
- Directed optimization of highly selective DPP9 inhibitors for chemical biology and translational research.From1 Nov 2023 → TodayFunding: FWO fellowships
- Characterization and validation of novel autophagy inducers identified via high-throughput screening: a therapeutic option for the treatment of advanced atherosclerosis.From1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- AUTAC- and PROTAC-mediated degradation of DPP9 to induce pyroptosis: a novel treatment strategy in acute myeloid leukemia.From1 Oct 2023 → TodayFunding: FWO junior postdoctoral fellowship
- Development of a pancreatic cancer drug-nanocarrier system selectively targeting tumour cells and tumour stroma to overcome treatment failure (PaCaNano).From1 Sep 2023 → TodayFunding: FWO research project (including WEAVE projects)
- OncoProToolsFrom1 Jun 2023 → TodayFunding: BOF - projects
- DPP9 degradation-induced pyroptosis for treatment of acute myeloid leukemia (DPP9-TACDrug).From1 Apr 2023 → TodayFunding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- Diagnostic and theranostic targeting of fibroblast activation protein (FAP) with goed nanoparticles decorated with FAPIs and FAPI fragments.From1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
Publications
21 - 30 of 129
- Molecular imaging of apoptosis(2021)
Authors: Lucas Beroske, Tim Van den Wyngaert, Sigrid Stroobants, Pieter Van Der Veken, Filipe Elvas
- Computational investigation of the catalytic mechanism and dynamics of Staphylococcus aureus glycosyltransferase towards development of novel antibiotics(2021)
Authors: Kenneth Goossens, Hans De Winter, Pieter Van Der Veken
Number of pages: 336 - The effect of a novel serine protease inhibitor on inflammation and intestinal permeability in a murine colitis transfer model(2021)
Authors: Hanne Van Spaendonk, Hannah Ceuleers, Annemieke Smet, Maya Berg, Jurgen Joossens, Pieter Van Der Veken, Sven Francque, Anne-Marie Lambeir, Joris De Man, Ingrid De Meester, et al.
Pages: 1 - 13 - Partial inhibition of glycolysis reduces atherogenesis independent of intraplaque neovascularization in mice(2020)
Authors: Paola Perrotta, Bieke Van der Veken, Pieter Van Der Veken, Isabel Pintelon, Laurence Roosens, Elias Adriaenssens, Vincent Timmerman, Pieter-Jan Guns, Guido De Meyer, Wim Martinet
Pages: 1168 - 1181 - [⁶⁸Ga-68]Ga-DATA(5m).SA.FAPi PET/CT: specific tracer-uptake in focal nodular hyperplasia and potential role in liver tumor imaging(2020)
Authors: Barbara Kreppel, Florian C. Gaertner, Milka Marinova, Ulrike Attenberger, Michael Meisenheimer, Marieta Toma, Glen Kristiansen, Georg Feldmann, Euy Sung Moon, Frank Roesch, et al.
Pages: 387 - 389 - Targeting fibroblast activation protein (FAP)(2020)
Authors: Euy Sung Moon, Gwendolyn Vliegen, Christel Vangestel, Sven De Bruycker, An Bracke, Elisabeth Eppard, Lukas Greifenstein, Benedikt Klasen, Vasko Kramer, Steven Staelens, et al.
- Development of novel chemical tools for bioorthogonal pretargeted PET imaging(2020)
Authors: Eduardo Ruivo, Koen Augustyns, Pieter Van Der Veken, Leonie Wyffels
Number of pages: 226 - Optimization of hydantoins as potent antimycobacterial decaprenylphosphoryl-β-D-ribose oxidase (DprE1) inhibitors(2020)
Authors: Eleni Pitta, Maciej Rogacki, Eugenia Meiler, Ruth Casanueva, Laura Guijarro, Sophie Huss, Eva Maria Lopez-Roman, Angel Santos-Villarejo, Koen Augustyns, Lluis Ballell, et al.
Pages: 5367 - 5386 - Lead optimization of phthalazinone phosphodiesterase inhibitors as novel antitrypanosomal compounds(2020)
Authors: Irene Garcìa Salado, Abhimanyu K. Singh, Carlos Moreno Cinos, Guna Sakaine, Marco Siderius, Pieter Van Der Veken, Tiffany van der Meer, Payman Sadek, Sheraz Gul, Louis Maes, et al.
Pages: 3485 - 3507 - Preclinical evaluation of a novel ¹⁸F-labeled dTCO-amide derivative for bioorthogonal pretargeted positron emission tomography imaging(2020)
Authors: Eduardo Ruivo, Filipe Elvas, Karuna Adhikari, Christel Vangestel, Glenn Van Haesendonck, Filip Lemière, Steven Staelens, Sigrid Stroobants, Pieter Van Der Veken, Leonie Wyffels, et al.
Pages: 4449 - 4456
Patents
1 - 10 of 10
- 3-(Benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. Stroke (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- Halogenated benzotropolones as ATG4B inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- KLK4 inhibitors (Inventor)